Table 1 Correlations between miR-10b-3p expression and clinicopathological parameters of ESCC patients
Characteristics | Training group (n = 93) | Test group (n = 102) | ||||
|---|---|---|---|---|---|---|
Low (n = 21) | High (n = 72) | P | Low (n = 27) | High (n = 75) | P | |
Gender | ||||||
 Male | 17 (22.1%) | 60 (77.9%) | 0.799 | 21 (25.0%) | 63 (75.0%) | 0.467 |
 Female | 4 (25.0%) | 12 (75.0%) | 6 (33.3%) | 12 (66.7%) | ||
Age | ||||||
  ≤ 60 | 6 (22.2%) | 21 (77.8%) | 0.958 | 8 (22.9%) | 27 (77.1%) | 0.550 |
 >60 | 15 (22.7%) | 51 (77.3%) | 19 (28.4%) | 48 (71.6%) | ||
Tumor size | ||||||
 < 5 cm | 10 (19.8%) | 41 (80.4%) | 0.450 | 20 (30.3%) | 46 (69.7%) | 0.235 |
  ≥ 5 cm | 11 (26.2%) | 31 (73.8%) | 7 (19.4%) | 29 (80.6%) | ||
Tumor stagea | ||||||
 T1+ T2 | 7 (31.8%) | 15 (68.2%) | 0.270 | 9 (39.1%) | 14 (60.9%) | 0.118 |
 T3+ T4 | 13 (20.3%) | 51 (79.7%) | 18 (22.8%) | 61 (77.2%) | ||
Histological grade | ||||||
 Well/moderate | 17 (23.0%) | 57 (77.0%) | 0.858 | 21 (25.3%) | 62 (74.7%) | 0.576 |
 Poor/NS | 4 (21.1%) | 15 (78.9%) | 6 (31.6%) | 13 (68.4%) | ||
Lymph node metastasis | ||||||
 Negative | 17 (37.8%) | 28 (62.2%) | 0.001 | 20 (33.9%) | 39 (66.1%) | 0.046 |
 Positive | 4 (8.3%) | 44 (91.7%) | 7 (16.3%) | 36 (83.7%) | ||
Clinical stagesa | ||||||
 I + II | 17 (35.4%) | 31 (64.6%) | 0.002 | 22 (37.9%) | 36 (62.1%) | 0.003 |
 III + IV | 3 (7.5%) | 37 (92.5%) | 5 (11.4%) | 39 (88.6%) | ||